SavedAdd your journal

Journals / Etlik Veteriner Mikrobiyoloji Dergisi / 2019 / Cilt: 30 - Sayı: 1

Antiviral Drug

Antiviral İlaçlar

Ali KÜÇÜK
Yakup YILDIRIM
Pages
100–108
Publication Date
2019-06-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this composition, information has been provided about antiviral agents developed to be used in treatment of viral infections threatening human and animal health.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Throughout history, viral diseases have always threatened lives of all humans and living beings in contact with them causing epidemics and pandemics.
📊
Key Findings & Data:Technological and health opportunities that started to develop at the beginning of the 20st century made it possible to convey studies and research on treatment of viral diseases.
💡
Conclusion & Impact:In this composition, information has been provided about antiviral agents developed to be used in treatment of viral infections threatening human and animal health.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Antiviral ilaç · virüs · Antiviral drug

Abstract

Throughout history, viral diseases have always threatened lives of all humans and living beings in contact with them causing epidemics and pandemics. These epidemics that caused death or destruction of millions of living beings also brought about the need for protection and treatment. Technological and health opportunities that started to develop at the beginning of the 20st century made it possible to convey studies and research on treatment of viral diseases. In this composition, information has been provided about antiviral agents developed to be used in treatment of viral infections threatening human and animal health.

Özet

Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim

🔖

Cite This Article

KÜÇÜK, A., YILDIRIM, Y. (2019). Antiviral Drug. Etlik Veteriner Mikrobiyoloji Dergisi, Cilt: 30 - Sayı: 1, 100–108. https://ajindex.com/articles/118592

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Adalsteinsson JA, Pan M, Kaushik S, Ungar J, (2018). Foscarnet-induced genital lesions: An overview with a case report. Dermatol Reports.10, 12-13.
  2. Adams J, Patel N, Mankaryous N, Tadros M, Miller CD, (2010). Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents. Ann Pharmacother. 44, 157–165.
  3. Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA, (2018). Proteases and protease inhibitors in infectious dis- eases. Med Res Rev. 38, 1295-1331. Air GM, (2012), İnfluenza neuraminidase. İnfluenza Other Respir Virus. 6,245-256.
  4. Al-Badr AA, Ajarim TDS, (2018). Ganciclovir. Brittin HG. Eds. Profiles of Drug Substances, Excipients and Related Methodology vol 43. Academic Press Inc, USA, 1-208.
  5. Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R, (2005). Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidinenucleosides, Antimicrob Agents Chemother. 49, 1081–1086.
  6. Angus P, Vaughan R, Xıong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S, (2003). Resistance to Adefovir Dipivoxil Therapy Associated With the Selection of a Novel Mutation in the HBV Polymerase. Gastroenterology. 125, 292-297.
  7. Arslan U, Ural O, Fındık D, (2008). Lamivudin tedavisi alan kronik hepatit B olgularında inno-lipa HBV DR yöntemi ile saptanan YMDD motif değişiklikleri, Mikrobiyol Bul. 42, 445-450.
  8. Berkhout B, Eggink D, Sanders RW, (2012). Is there a future for antiviral fusion inhibitors. Białek-Pietras M, Olejniczak AB, Paradowska E, Studzinska M, Jabłonska A, Lesnikowski ZJ, (2018). Synthesis, suscep- tibility to enzymatic phosphorylation, cytotoxicity and in vitro antiviral activity of lipophilic pyrimidine nucleoside/ carborane conjugates. J Organomet Chem. 865, 166-172.
  9. Chang T, Gish R, De Man R, (2006). A comparison of ente- cavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010. 12. Charpentier C, Camacho R, Ruelle J, Eberle J, Gurtler L, Pironti A, Sturmer M, Brun-Vezinet F, Kaiser R, Descamps D, Obermeier M, (2015). HIV-2EU-supporting standard- ized HIV-2 drug-resistance interpretation in Europe: an update. Clin Infect Dis. 61, 1346-1347.
  10. Chou TY, Hong BY, (2014). Ganciclovir ophthalmic gel %0.15 for the treatment of acute herpetic keratitis: back- ground, effectiveness, tolerability, safety, and future appli- cations. Ther Clin Risk Manag. 10, 665–681. Cih